Charles River Laboratories International (CRL) Projected to Post Earnings on Wednesday

Key Points

• Charles River Laboratories International is set to release its Q2 2025 earnings on August 6th, with expectations of earnings per share at $2.50 and revenue of $983.76 million.
• In its last quarterly earnings, the company reported earnings per share of $2.34, exceeding analysts' estimates by $0.28, despite a 2.7% decline in revenue year-over-year.
• Analysts have mixed opinions on the stock, with a consensus rating of "Hold" and various target price adjustments, including Citigroup raising its target from $150 to $200.

Charles River Laboratories International (NYSE:CRL - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of $2.50 per share and revenue of $983.76 million for the quarter. Charles River Laboratories International has set its FY 2025 guidance at 9.300-9.800 EPS.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.06 by $0.28. The firm had revenue of $984.17 million for the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The firm's quarterly revenue was down 2.7% on a year-over-year basis. During the same period in the prior year, the company posted $2.27 earnings per share. On average, analysts expect Charles River Laboratories International to post $9 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Charles River Laboratories International Stock Down 1.6%

CRL traded down $2.75 during trading on Friday, hitting $166.89. The company had a trading volume of 821,687 shares, compared to its average volume of 783,127. The company has a market cap of $8.20 billion, a PE ratio of -256.75, a P/E/G ratio of 5.65 and a beta of 1.48. The business has a 50-day moving average of $153.56 and a 200-day moving average of $149.56. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.43 and a quick ratio of 1.16. Charles River Laboratories International has a 1-year low of $91.86 and a 1-year high of $236.88.

Analyst Ratings Changes

A number of brokerages have weighed in on CRL. Redburn Atlantic raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and dropped their target price for the stock from $188.00 to $182.00 in a report on Friday, May 23rd. Mizuho dropped their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. Wall Street Zen cut shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a report on Saturday, July 5th. Robert W. Baird increased their target price on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a report on Thursday, May 8th. Finally, Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Charles River Laboratories International presently has an average rating of "Hold" and a consensus target price of $174.54.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the transaction, the executive vice president owned 19,513 shares in the company, valued at approximately $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.30% of the company's stock.

Hedge Funds Weigh In On Charles River Laboratories International

An institutional investor recently bought a new position in Charles River Laboratories International stock. Empowered Funds LLC bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 2,776 shares of the medical research company's stock, valued at approximately $418,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).